Compare ResMed Inc. (RMD) vs S&P500 ETF (SPY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ResMed Inc. vs S&P500 ETF — how do they compare? ResMed Inc. trades at $194.03 (market cap $28.81B), while S&P500 ETF trades at $747.63. The key difference: ResMed Inc. pays a 1.21% dividend while S&P500 ETF pays none, and S&P500 ETF is trading nearer its 52-week high, ResMed Inc. nearer its low. Which is the better fit depends on your goals.
| RMD | SPY | |
|---|---|---|
Market Cap | $28.81B | — |
Sector | Health | — |
52-Week High | $293.73 | $759.55 |
52-Week Low | $182.82 | $621.75 |
Enterprise Value | $27.99B | — |
Dividend Yield | 1.21% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ResMed (RMD) trades at $195.8, down 1.6% on the day, with a bearish technical signal but strong fundamentals. Recent quarterly earnings have consistently beaten estimates, with Q1 2026 EPS of $2.86 exceeding the $2.80 forecast. The company sold its MatrixCare business for $490 million in July 2026 to sharpen focus on connected care, signaling strategic refinement. Revenue growth remains robust, climbing to $5.15 billion in 2025, with net income margins expanding to 27.44%.
The outlook is supported by solid earnings momentum and a consensus price target of $245.88, implying 25.6% upside. Risks include competitive pressures in medical equipment and reliance on sleep apnea market growth. Analyst sentiment is mixed with 40% buy ratings, but institutional selling by Baader Bank in Q1 2026 warrants monitoring.
SPY, the SPDR S&P 500 ETF, trades at $748.32, up 0.7% with a bearish technical bias as it faces resistance near $747-$754. The ETF reflects broad market dynamics, with recent news highlighting AI-driven industrial growth and concerns over S&P 500 valuations nearing historical highs. A dividend of $1.90 is scheduled for July 2026, providing income amid volatility.
Outlook remains cautious due to technical resistance and valuation concerns, but long-term exposure to large-cap US equities offers diversification. Risks include market overvaluation and economic headwinds, while institutional holdings support stability. Investors should weigh technical signals against fundamental market breadth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →About S&P500 ETF
The ETF is designed to track the performance of the securities and the stocks in the S&P 500 Index. To maintain the composition and weightings, the advisor adjusts the ETF from time to time to conform to periodic changes in the index target.
Read more on SPY →
